T he activation of blood coagulation cascade is evident in a variety of acute liver injuries. (1) (2) (3) Growing evidence indicates that coagulation is not merely a process reactive to toxicity, but rather a critical determinant of acute liver disease progression. (4) (5) (6) (7) (8) (9) (10) A reduction in liver damage by administration of anticoagulant has been observed in a variety of animal models, including acetaminophen-induced hepatotoxicity and hepatic ischemia reperfusion injury, as well as liver injury caused by lipopolysaccharide/ D-galactosamine, anti-Fas antibody, and concanavalin A (ConA). (4) (5) (6) (7) (8) (9) (10) The alleviation of liver injury in hepatocyte tissue factor (TF)-deficient mice further demonstrates the significance of intrahepatic activation of coagulation (IAOC) in acute liver injury. (11, 12) However, the mechanisms by which coagulation cascade exacerbates liver disease are not completely understood.
To gain mechanistic insights and identify key players involved in intrahepatic coagulation, we used a mouse model of ConA-induced liver injury (CILI), in Abbreviations: ALT, alanine aminotransferase; ANOVA, analysis of variance; Chi3l1, chitinase 3-like 1; CILI, ConA-induced liver injury; ConA, concanavalin A; DMEM, Dulbecco's modified Eagle's medium; ELISA, enzyme-linked immunosorbent assay; H&E, hematoxylin & eosin; IAOC, intrahepatic activation of coagulation; IFN-c, interferon c; IL, interleukin; JNK, c-Jun amino terminal kinase; LSEC, liver sinusoid endothelial cell; MU, macrophages; MAPK, mitogen-activated protein kinase; mRNA, messenger RNA; NKT, natural killer T; qRT-PCR, quantitative reversetranscription polymerase chain reaction; rChi3l1, recombinant Chi3l1; TAT, thrombin anti-thrombin complex; TNF-a, tumor necrosis factor a; TSEC, transformed sinusoid endothelial cell.
which excessive IAOC drives tissue damage. (9, 10, 13, 14) ConA is a lectin with agglutination activities resulting in prominent intrasinusoidal stasis. This phenomenon is manifested by erythrocyte agglutination, adherence of lymphocytes and neutrophils to the endothelium, and platelet aggregation/degranulation. Together, these events result in a marked decrease of intrahepatic blood flow and elevated portal pressure, culminating in severe liver injury. (9, 15) It has been demonstrated that anticoagulant treatment significantly attenuates CILI, supporting that the sinusoidal hypercoagulation with increased thrombin generation plays a paramount role in the injury process. (9, 14) To identify mediators of IAOC, we screened a panel of soluble factors produced by innate and adaptive immune cells that are known to be activated by ConA. We found that both messenger RNA (mRNA) and protein levels of chitinase 3-like 1 (Chi3l1) were significantly elevated after ConA challenge.
Chi3l1 is a chitinase-like soluble protein without chitinase activities. (16) It is produced by multiple cell types, including neutrophils, macrophages (MU), chondrocytes, synovial cells, smooth muscle cells, endothelial cells, and tumor cells. (16, 17) Increased levels of Chi3l1 have been correlated with poor prognosis in liver diseases, such as hepatic fibrosis, nonalcoholic fatty liver, alcoholic liver disease, and hepatocellular carcinoma. (18, 19) However, the biological functions of Chi3l1 in the liver remain mysterious. Our study indicates that Chi3l1 plays a critical role in promoting IAOC and liver injury through inducing tissue factor (TF) expression via mitogen-activated protein kinase (MAPK) activation. This discloses a pro-coagulant function of Chi3l1. The findings suggest that Chi3l1 may serve as a therapeutic target in the treatment of liver disease associated with intrahepatic coagulation.
Materials and Methods

ANIMAL EXPERIMENTS AND PROCEDURES
All animal experiments were performed according to guidelines from the University of Colorado Denver Institutional Animal Care and Use Committee. Eightto 12-week-old mice were injected with 15 mg/kg ConA (Sigma, St. Louis, MO) intravenously. Male and female mice responded to ConA treatment similarly, although their dose responses were different ( Fig. 1D and Supporting Fig. S1 ). (20) Because most published studies have used male mice, (21) we used male mice in our study as well. In some experiments, mice received ConA followed immediately by injection with antimurine interferon c (IFN-c) antibody (500 ng, Peprotech 500 p119), anti-murine tumor necrosis factor a (TNF-a) antibody (500 ng, Peprotech 500-P64), normal rabbit immunoglobulin G (Peprotech, 500-p00), recombinant Chi3l1 (rChi3l1; 500 ng, Sino Biological 50929-M08H) by intraperitoneal or TF protein (500 ng, R&D 3178-PA-010), anti-TF antibody (1H1, 500 lg, Genentech Inc.) by intravenous injection. FK506 (32 mg/kg body weight, Cayman 104987-11-3) was performed as previously described. (9) The levels of alanine aminotransferase (ALT) in serum and IFN-c, TNF-a, and Chi3l1 in serum and liver tissues were determined using commercially available kits (ALT, Teco Diagnostics; enzyme-linked immunosorbent assay [ELISA], R&D).
HISTOLOGY
Hematoxylin & eosin (H&E) were performed by the Histology core at CUAMC on paraffin sections. Fibrin(ogen) was performed as described previously. (24) TF was stained with anti-mouse TF antibody (abcam151748). CD41 cells were stained with antimouse CD41 antibody (BD Bioscience, Clone MWReg 30) followed by Alexa 488-conjugated donkey anti-rat secondary antibody (Invitrogen Life Technologies).
THROMBIN ANTI-THROMBIN III COMPLEX (TAT) MEASUREMENT
Plasma were collected by way of retro-orbital puncture into a 3.2% solution of sodium citrate. thrombin antithrombin complex (TAT) was measured by a commercially available kit (AssayMax, catalog #EMT1020-1).
CELL CULTURE AND TREATMENT WITH CYTOKINES OR INHIBITORS
Isolated primary liver sinusoid endothelial cells (LSECs) and MU were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum and treated with the indicated amount of murine recombinant rChi3l1, IFN-c (Peprotech 315-05), or TNF-a (Peprotech 500-P64) for various times. In some experiments, the cells were pretreated with inhibitors for 1 hour before rChi3l1 treatment. The concentrations of the inhibitors used were as follows: c-Jun amino terminal kinase (JNK) inhibitor (20 lM SP600125, sigma S5567), P38 inhibitor (20 lM SB203580, sigma S8307), and ERK inhibitor (20 lM U0126, sigma U120). The transformed sinusoid endothelial cells (TSECs) were a generous gift from Vijay Shah (Mayo Clinic, Rochester, MN). LSECs or TSECs were cultured in DMEM supplemented with 10% ECGS (SclenCell, catalog #1052).
FLOW CYTOMETRIC ANALYSIS
Intracellular staining for IFN-c, TNF-a, and interleukin (IL)-4 was performed as described previously. (24) STATISTICAL ANALYSIS Data are presented as the mean 6 SEM. Statistical analyses were performed using GraphPad Prism (GraphPad Software). Comparisons between two groups were analyzed using an unpaired Student t test.
Comparisons among multiple groups (n 3) were analyzed using one-way analysis of variance (ANOVA). A P value less than 0.05 was considered significant. Positive areas of protein expression were analyzed by ImageJ software.
Results
Chi3l1 CONTRIBUTES TO CILI
ConA challenge causes soluble mediators released by a variety of immune cells in the liver, including natural cells, natural killer T (NKT) cells, neutrophils, MU, and T cells. (25) (26) (27) (28) We measured the hepatic mRNA expression of a panel of these mediators in wild-type (WT) C57Bl/6J mice at 3 hours after ConA challenge (Supporting Fig. S2 ). Among these mediators, both mRNA and protein levels of Chi3l1 were dramatically increased post-ConA ( Fig. 1A-C) . Interestingly, we found that mice deficient in Chi3l1 (Chi3l1
2/2
) were less susceptible to CILI than WT mice. The ALT levels in Chi3l1 2/2 mice were 1200
and 600 IU/L at 8 and 24 hours, respectively, whereas the levels in WT mice were as high as 5600 IU/L (Fig.  1D ). In accordance with the reduced ALT activities, the histopathology of the liver showed less hepatocyte injury in Chi3l1 2/2 ( Fig. 1, E&F) . These results suggest that Chi3l1 is produced and released after ConA challenge and it contributes to CILI.
ConA-INDUCED IMMUNE RESPONSES ARE NOT AFFECTED BY Chi3l1
The activation of immune cells (T, NKT, neutrophils, MU) and their cytokine products, especially IFN-c and TNF-a, have been reported to contribute to CILI. (10, 21, 25, 26) We first investigated whether Chi3l1 could potentially affect these immune cells and their cytokine production. Our data showed no significant differences in the number of CD3 1 T cells in the livers of WT and Chi3l1 2/2 mice ( Fig. 2A,B) . The amounts of IFN-c and TNF-a production by hepatic T cells were also similar between WT and Chi3l1 1 T cell-derived IFN-c (C) and TNF-a (D) were measured by intracellular staining and flow cytometry (n 5 5 mice per group). (E-F) At 3 and 6 hours after ConA administration, Serum levels of IFN-c (E) and TNF-a (F) were measured by ELISA (n 5 4-7 mice per group). P values were determined using a two-tailed, unpaired t test (ns, not significant).
even higher in Chi3l1
2/2 mice than in WT mice at 3 hours post-ConA (Fig. 2F) . NKT cells and their IL-4 production are important in CILI. (25) However, our data (Supporting Fig. S3A,B) show that the numbers of hepatic NKT cells and their intracellular expression of IL-4 were comparable between WT and Chi3l1 2/2 mice. It has been reported that neutrophils and macrophages are important in promoting T cell recruitment and subsequent development of hepatitis. (10, 26, 29) However, we did not find any differences in the numbers of neutrophils or macrophages in the liver between WT and Chi3l1 2/2 mice (Supporting Fig. S4A-D) . Taken together, these data suggest that Chi3l1 does not affect ConA-induced activation of the innate and adaptive immune systems.
Chi3l1-DEFICIENCY ATTENUATES CILI
Aside from the proinflammatory immune responses, IAOC represents another critical underlying mechanism for CILI. (9, 10) To explore whether Chi3l1 contributes to CILI through promoting coagulation, we compared fibrin(ogen) deposition, TAT levels, and platelet influx between WT and Chi3l1 2/2 mice. WT mice had higher levels of fibrin(ogen) deposition (Fig.  3A ,B) in liver tissues than Chi3l1 2/2 mice at both 6 and 24 hours post-ConA. TAT complexes are used as an indicator for thrombin formation in the circulation. (30) Our data show that the plasma TAT levels were significantly elevated after ConA challenge in WT mice, but not in Chi3l1 2/2 mice (Fig. 3E) . Moreover, platelet influx significantly increased at 3 hours post-ConA, but there was no difference between WT and Chi3l1 2/2 mice (Supporting Fig. S5A,B ). Taken together, these results demonstrate that Chi3l1 is critically involved in IAOC.
THE EFFECT OF Chi3l1 ON CILI DEPENDS ON T CELL-DERIVED IFN-c AND TNF-a
It has been reported that the activation of T cells and their production of IFN-c and TNF-a contribute to CILI. (10) To determine whether Chi3l1 is a downstream mediator of this pathway, we treated WT mice with a T cell suppressor, FK506, 1 hour before ConA challenge. As expected, FK506 treatment inhibited ConA-induced up-regulation of IFN-c and TNF-a mRNA levels in the liver (Fig. 4A) . Interestingly, the mRNA expression levels of Chi3l1 were also markedly reduced by FK506 (Fig. 4A) . Consistently, Chi3l1 protein expression was also dramatically reduced by the FK506 treatment in the liver and serum (Fig. 4B,C) . These results indicate that T cell activation is necessary to induce Chi3l1 production. Systematic time course studies also revealed that the elevation of IFN-c and TNF-a preceded that of Chi3l1 (Fig. 5A) . Thus, to determine whether IFN-c and TNF-a induce Chi3l1 expression, we treated mice with anti-IFN-c and anti-TNF-a antibodies before ConA challenge. Blocking IFN-c and TNF-a prevented ConA-induced up-regulation of both mRNA and protein expressions of Chi3l1 (Fig. 5B-D) .
In agreement with the notion that IFN-c and TNF-a are key players causing CILI, our data show that blocking IFN-c and TNF-a significantly reduced fibrin(ogen) deposition, the degree of hepatic necrosis, and ALT activities (Supporting Fig. S6A-C) . To further demonstrate that Chi3l1 can be induced by IFN-c and TNF-a, we isolated LSECs and hepatic MU from na€ ıve WT mice and treated the cells with either IFN-c or TNF-a. We found that both IFN-c and TNF-a could significantly up-regulate Chi3l1 mRNA expression in LSECs and hepatic MU (Fig. 5E,F) . These data suggest that IFN-c and TNF-a are potent regulators in the induction of Chi3l1 both in vivo and in vitro.
Chi3l1 PLAYS A CRUCIAL ROLE IN THE INDUCTION OF TF
To understand the mechanism by which Chi3l1 contributes to CILI, we screened several coagulation factors after ConA treatment (Supporting Fig. S7 ). The baseline levels of the coagulation factors in WT and Chi3l1 2/2 mice were similar (Supporting Fig.  S7A ). At 3 hours after ConA treatment, the hepatic mRNA levels of TF, PAI-1, anti-thrombin, protein C, and fibrinogen were significantly lower in Chi3l1 2/ 2 mice compared with WT mice (Supporting Fig.  S7B ). It has been reported that TF-mediated IAOC contributes to CILI. (10) Through systematic time course studies, we also noticed that TF induction proceeds coagulation and liver injury caused by ConA (Supporting Fig. S8A,B) , indicating that Chi3l1 may be important in inducing TF production, thereby promoting coagulation. We found that compared with WT mice, Chi3l1 2/2 mice expressed significantly lower mRNA and protein levels of TF (Fig. 6A-C and Supporting Fig. S9 ). To further demonstrate that Chi3l1 can induce TF, we reconstituted Chi3l1 2/2 mice with recombinant Chi3l1 (rChi3l1). As shown in Figure 6E , administration of rChi3l1 significantly increased the mRNA expression of TF in the liver. The combination of rChi3l1 and ConA dramatically up-regulated the mRNA and protein levels of TF mice with rChi3l1 significantly increased the levels of fibrin(ogen) deposition in the liver and augmented CILI, as evident by the increased ALT activities and worsened histology (Fig. 6D,F and Supporting Fig.  S10B ). These data indicate that Chi3l1 plays a critical role in IAOC through the induction of TF. Interestingly, in the absence of ConA treatment, rChi3l1 alone did not cause coagulation in Chi3l1 2/2 mice, suggesting that Chi3l1 regulates the expression of TF, but the coagulant activity of TF is induced by ConA in a Chi3l1-independent manner.
TF INDUCED BY Chi3l1 DRIVES ACTIVATION OF COAGULATION
To confirm that TF drives IAOC, we blocked endogenous TF protein using an anti-TF (1H1) antibody and found that ConA-induced IAOC and liver injury were decreased significantly (Supporting Fig. S11A,B) . To further examine our hypothesis that in the Chi3l1 2/2 mice, it is the attenuated TF production that results in reduced liver injury, we administered exogenous rTF to Chi3l1 2/2 mice. Because the rTF we injected was not functionally activated by relipidation and lacked procoagulant activity, it alone did not cause systemic coagulation (Supporting Fig.  S11C ). However, in the presence of ConA treatment, likely caused activation of rTF, we observed significant increases of ConA-induced IAOC and liver injury in Chi3l1 2/2 mice (Fig. 7A,B) . These data suggest that Chi3l1 induces TF expression but does not affect its activation. To further substantiate the role of Chi3l1 in TF induction, we reconstituted Chi3l1 2/2 mice with rChi3l1 while neutralizing TF. The data reveal that rChi3l1-induced worsening of CILI and IAOC was abrogated by TF neutralization (Fig. 7) . (B-C) TF protein expression was measured by way of immuno-histochemical staining (magnification 3200) and quantified in C. Representative images were from at least 4 mice each group. Treat Chi3l1 2/2 mice with mouse recombinant Chi3l1 (rChi3l1) by intraperitoneal injection at the same time of ConA administration. (D) The levels of TF and fibrin(ogen) were measured by immunohistochemical staining (magnification 3200). H&E-stained liver sections are shown with outlined necrotic areas (magnification 3100). Representative images were from at least 4 mice per group. (E) Hepatic TF mRNA expression levels were measured 3 hours after ConA treatment. (F) Serum ALT activities were determined 24 hours after ConA treatment (n 5 4-6 mice per group). P values were determined using a two-tailed, unpaired t test (A, C) or one-way ANOVA (E, F) (ns, not significant).
Chi3l1 INDUCES TF EXPRESSION THROUGH MAPK SIGNALING PATHWAY
It has been reported that TF is expressed by hepatic MU, LSECs, and hepatocytes during CILI. (10) We examined TF mRNA expression in hepatic MU, LSECs, and hepatocytes from both na€ ıve WT and Chi3l1 2/2 mice and mice treated with ConA for 3 hours. The baseline levels of TF mRNA in hepatocytes are about 8-fold higher than that in hepatic MU and LSECs in both WT and Chi3l1 2/2 mice (Fig. 8A) . After ConA treatment, TF mRNA increased 18-fold in hepatic MU of both WT and Chi3l1 2/2 mice. However, TF mRNA increased nearly 40-fold in LSECs and 45-fold in hepatocytes of WT mice but only approximately 9-fold in LSECs and 19-fold in hepatocytes of Chi3l1 2/2 mice (Fig. 8A) . To directly address whether Chi3l1 induces TF in these cells, we stimulated hepatic MU, LSECs, and hepatocytes isolated from na€ ıve WT mice with rChi3l1. TF mRNA expression was induced in LSECs and hepatocytes but not in hepatic MU in vitro (Fig. 8B) . Interestingly, hepatocytes are more responsive to rChi3l1. The elevation of TF mRNA levels is much more dramatic in hepatocytes (80-fold) than in LSECs (3-fold) (Fig.  8B) . The measurement of endotoxin levels and experiment using polymyxin B ruled out the possibility of TF induction due to endotoxin contamination of rChi3l1 (Supporting Fig. S12A,B) . To compare the potencies of IFN-c, TNF-a, and Chi3l1 in the induction of TF, we treated LSECs with the concentrations of these mediators detected in serum at 3 hours after ConA treatment. Among the three potential mediators, only rChi3l1 induced TF up-regulation (Fig. 8C) . These data further suggest that Chi3l1 is an important downstream mediator of IFN-c/TNF-a in inducing TF expression. To shed light on the molecular mechanisms by which Chi3l1 regulates TF expression, we screened several potential signaling pathways. Results are from three independent experiments. P values were determined using ANOVA (A, C, E) or a twotailed, unpaired t test (B).
Our data reveal that Chi3l1 activated AKT and the MAPK family, including ERK1/2, JNK, and p38 in the TSEC cell line (Fig. 8D) . However, rChi3l1 did not activate nuclear factor kappa B or signal transducer and activator of transcription 1 (Fig. 8D) . We then treated LSECs with rChi3l1 in combination with various MAPK inhibitors (JNK: SP600125; p38: SB203580; ERK: U0126), all of which significantly reduced TF expression levels (Fig. 8E) . These results suggest Chi3l1 induces TF expression by activating the MAPK signaling pathway.
Discussion
In this study, we demonstrate that after ConA administration, activated T cells produce IFN-c and TNF-a, which induce Chi3l1 production. The released Chi3l1 triggers MAPK activation and promotes TF production by LSECs and hepatocytes, thereby initiating IAOC and leading to liver injury (Fig. 8F) .
Our observations that 1) IFN-c and TNF-a production precede Chi3l1 release (Fig. 5A) , 2) T cell suppression abrogates the elevation of Chi3l1 (Fig. 4A-C) , and 3) neutralization of IFN-c and TNF-a dramatically reduces the levels of Chi3l1 (Fig. 5B-D) suggest that ConA-triggered T cell activation and the production of IFN-c and TNF-a play crucial roles in the up-regulation of Chi3l1. It has been reported that IFN-c and TNF-a are important in inducing TF production and promoting hepatic thrombosis within the liver. (10) However, after ConA treatment, WT and Chi3l1 2/2 mice produce similar amounts of IFN-c and TNF-a (Fig. 2C-F) , but TF expression is much lower in Chi3l1 2/2 mice ( Fig. 6A-C; Supporting Fig. S9) . Moreover, at the levels that can be detected in vivo, IFN-c and TNF-a could not directly induce TF expression in vitro (Fig. 8C) . These findings suggest that Chi3l1 is one of the downstream mediators of IFN-c and TNF-a that plays an important role in inducing TF expression. Nonetheless, blocking IFN-c/TNF-a did not completely abrogate Chi3l1 expression (Fig. 5) . Thus, we cannot exclude the possibility that ConA may directly induce Chi3l1 expression, as ConA can activate LSECs and MUs. (9, 29, 31) Aside from IFN-c and TNF-a, other cytokines produced by ConA-activated T cells may also induce Chi3l1 expression. For example, it has been reported that the expression of Chi3l1 can be regulated by IL-6, IL-13, IL-18, and IL-1b. (32) (33) (34) (35) Our data show that IFN-c and TNF-a induce Chi3l1 expression in both LSECs and hepatic MU (Fig.  5E,F ). However, it is possible that other cells in the liver may also produce Chi3l1. Therefore, questions such as the cellular source of Chi3l1 and the receptors through which it signals warrant further research. T cell activation plays a critical role in the mechanism of CILI. (21) Moreover, IFN-c and TNF-a, which are produced by ConA-activated T cells, are critical in mediating tissue damage. In addition to triggering T cell activation, ConA has agglutination properties that cause stasis of blood components in liver sinusoids, preceding liver damage. (9) Ample evidence suggests that ConA-induced microcirculatory disturbance is of paramount importance contributing to CILI. (9, 10, 13, 14) Anticoagulant (heparin, cyproheptadine, and antithrombin III) pretreatment decreases hepatic injury by reducing hemostasis, but it does not affect inflammatory responses. (9, 14) In agreement with these findings, our data demonstrate that Chi3l1 deficiency confers a profound resistance to CILI without impairing T cell activation or inhibiting IFN-c and TNF-a production (Fig. 2) . In contrast, ConAinduced IAOC is markedly attenuated in Chi3l1 2/2 mice (Fig. 3) . Taken together, our study and other published reports demonstrate that ConA-induced IAOC and T cell activation are both critical events contributing to liver injury.
TF initiates coagulation and plays an integral role in blood coagulation and thrombin generation. (11) Our data suggest that in Chi3l1 2/2 mice, it is the reduced TF expression that results in attenuated CILI (Figs. 6 and 7). Both mRNA and protein levels of TF are markedly lower in the livers of Chi3l1 2/2 compared with WT mice ( Fig. 6A-C; Supporting Fig. S9 ).
Reconstituting Chi3l1
2/2 mice with rChi3l1 dramatically increased the TF mRNA and protein expressions and also augmented intrahepatic coagulation and CILI ( Fig. 6D-F; Supporting Fig. S7 ). Our data showed that administering exogenous TF alone did not cause coagulation, as the TAT level was not increased (Supporting Fig. S11C ). Although TF is important in initiating coagulation, endothelial activation/injury resulting in platelet aggregation and activation is also required. (36) In Chi3l1 2/2 mice treated with ConA, the platelets were recruited similarly as in WT mice (Supporting Fig. S5 ), but coagulation was suppressed (Fig. 3) due to a lack of TF (Fig. 7A) . Thus, administering exogenous TF could promote coagulation in ConA-treated Chi3l1 2/2 mice, recapitulating the IAOC and liver injury observed in WT mice.
Moreover, neutralizing TF abrogated the effect of rChi3l1 treatment in Chi3l1 2/2 mice (Fig. 7C,D) , suggesting that TF contributes to CILI and that the absence of Chi3l1 results in reduced TF expression and attenuated CILI in Chi3l1 2/2 mice. It has been reported that hepatocyte-derived TF contributes to IAOC caused by treatment with acetaminophen. (11, 12) Our data show that Chi3l1 induces TF expression in both hepatocytes and LSEC ( Fig. 8B; Supporting Fig.  S9 ), suggesting that both cell types may be important source of TF production in CILI.
Liver diseases are consistently associated with coagulation activation mediated by TF. (10, (37) (38) (39) TFdependent activation of the coagulation cascade occurs and contributes to the progression of acute cholestatic hepatitis caused by a-naphthylisothiocyanate. (38) Myeloid cell-derived TF plays an important role in modulating hepatic necrosis during cholestasis. (39) In TFdeficient mice, overdose of acetaminophen-induced liver injury and activation of coagulation are significantly reduced. (12) Hematopoietic cell-derived TF is required for liver inflammation and steatosis in nonalcoholic fatty liver disease. (40) TF pathway contributes to liver fibrosis induced by chronic cholestasis by increasing expression of the aVb6 integrin. (41) Administration of TF-antisense oligodeoxynucleotides successfully prevents monocrotaline/lipopolysaccharideinduced liver injury. (37) Therefore, the identification of Chi3L1 as a regulator of TF indicates an important role of Chi3l1 in liver diseases.
In conclusion, the present study demonstrates a procoagulant function of Chi3l1 and provides evidence that Chi3l1 induces TF production via MAPK activation. These findings identify Chi3l1 as a potential therapeutic target in treating coagulopathy in liver diseases and potentially other coagulation disorders.
